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Abstract 22 
Background: Chemoresistance remains one of the obstacles to overcome in the treatment of 23 
breast cancer. S100 calcium-binding protein P (S100P) has been observed to be overexpressed 24 
in several cancers and has been associated with drug resistance, metastasis, and prognosis. 25 
However, the role of S100P in chemoresistance in breast cancer has not been thoroughly 26 
determined. Methods: Immunohistochemistry was used to evaluate the expression level of 27 
S100P protein in 22 pairs (pre-chemo and post-chemo) of breast cancer tissue from patients 28 
who underwent neoadjuvant chemotherapy. The influence of S100P on the biological behavior 29 
and chemosensitivity of breast cancer cells was then investigated. Results: The protein level 30 
of S100P in breast cancer tissue was significantly higher than in benign fibroadenoma 31 
(p<0.001). The S100P expression level was shown to be decreased by 46.55% after 32 
neoadjuvant chemotherapy (p=0.015). Subgroup analysis revealed that S100P reduction 33 
(57.58%) was mainly observed in the HER2+ tumors (p=0.027). Our in-vitro experiments 34 
showed that the knockdown of S100P suppressed the proliferation, adhesion, migrative and 35 
invasive abilities of T47D and SK-BR-3 breast cancer cells. We further demonstrated that this 36 
knockdown increased the chemoresistance to paclitaxel and cisplatin in SK-BR-3 cells. We 37 
found S100P exerted its function by upregulating NF-κB, CCND1 and Vimentin, but 38 
downregulating E-cadherin.  Conclusions: S100P promotes the aggressive properties of breast 39 
cancer cells and may be considered as a promising therapeutic target. Moreover, S100P can be 40 
used to predict the therapeutic effect of chemotherapy in HER2+ breast cancer patients. 41 
 42 
1. Introduction 43 
Breast cancer is the most common malignancy and the second leading cause of cancer death in 44 
women [1].  Chemotherapy is widely applied to improve the survival of patients with breast 45 
cancer. However, some patients inevitably manifest chemoresistance in either an intrinsic or an 46 
acquired manner.  It has been a great challenge to tackle this problem for the better treatments 47 
of those breast cancer patients. This is particularly the case for patients with triple-negative 48 
breast cancer type or metastasis because the response to chemotherapeutic drugs may be vital 49 
for them to survive [2]. Therefore, it is a prerequisite to unveil the complicated mechanisms 50 
underlying the chemoresistance before better treatment could be developed to fulfill the need 51 
clinically. 52 
The S100 family consists of more than 20 small dimeric Ca2+-binding proteins, and is the 53 
largest group of the helix-loop-helix (EF-hand) superfamily [3]. S100 proteins are found to be 54 
involved in the regulation of calcium homeostasis, cell proliferation and apoptosis, cell 55 
invasion and motility, cancer metastasis, angiogenesis, cytoskeleton interactions, protein 56 
phosphorylation, regulation of transcriptional factors, autoimmunity, chemotaxis and 57 
inflammation [4]. S100P was originally identified in the human placenta [5] and is expressed 58 
in other organs such as the stomach, urinary bladder and bone marrow [6]. It contains a 59 
characteristic structural domain known as the EF-hand motif, which exists as intracellular or 60 
secreted homo- or hetero-dimers with composition depending on the cellular context [7]. The 61 
functions of S100P are mainly attributed to its interaction with or regulation of several 62 
molecules that regulate actin cytoskeleton dynamics and extracellular matrix remodeling, 63 
including Ezrin, IQGAP1, myosin IIA, cathepsin D, and phosphorylated cofilin [8; 9; 10; 11]. 64 
S100P acts as a signaling molecule in intracellular components and the extracellular matrix [12; 65 
13]. Although the mechanisms that regulate S100P have not been fully documented, DNA 66 
microarray indicates that S100P is upregulated by estradiol [14], progesterone [15] and HER2 67 
overexpression [16], which is in line with the clinical findings that high S100P levels are related 68 
to ER/PR and HER2 overexpressing tumors. The significant association between S100P and 69 
ER expression implies that S100P is involved in the early stages of breast carcinogenesis [17]. 70 
S100P is also linked to the immortalization of breast epithelial cells in vitro, tumor progression 71 
and early relapse in patients [17; 18; 19]. 72 
S100P has recently attracted great attention due to its implication in malignant transformation 73 
and tumor progression, and in predicting prognosis and metastasis in several cancer types [20]. 74 
The implication of S100P in the carcinogenesis and progression of breast cancer has also been 75 
reported [17; 21]. S100P expression is elevated in triple-negative breast cancer (TNBC) tissues 76 
[22] and associated with poor survival of the TNBC patients[23]. TNBC patients with the low 77 
cytoplasmic levels of both S100P and Ezrin have been shown to confer a better disease-free 78 
survival (DFS) compared to other TNBC patients [24]. S100P is thought to exerts its oncogenic 79 
activities via the activation of the receptor for advanced glycation end products (RAGE) [25]. 80 
The extracellular ligand-binding domain of RAGE can bind to several ligands, including S100P, 81 
to initiate downstream signalling pathways that promote cell proliferation, viability and 82 
motility. Blocking S100P interaction with RAGE is sufficient to inhibit the growth of tumours 83 
[26].  84 
Additionally, S100P dimers, formed in response to the increase in cellular calcium 85 
concentrations, can bind and activate the cytoplasmic protein Ezrin [7]. This interaction 86 
promotes trans-endothelial migration (TEM) in patients with lung cancer, pancreatic cancer 87 
and TNBC [24]. Moreover, S100P enhances cell proliferation by upregulating cyclin D1 and 88 
CDK2 in human hepatocellular carcinoma [27]. NORAD overexpression in the TNBC cell line 89 
MDA-MB-231 can block the interaction of S100P with IQGAP1 and p53, leading to the 90 
downregulation of cathepsin D and a reduction in cofilin phosphorylation [28]. The protein 91 
accumulation of S100P at tumor sites also stimulates tumor invasion by inducing angiogenesis 92 
[29]. Although S100P is mainly located in the cell nucleus and cytoplasm, it can also be 93 
secreted into the extracellular matrix in an autocrine or paracrine manner [30]. High plasma 94 
levels of S100P correlate robustly with poor prognosis of metastatic breast cancer (MBC) 95 
patients. In addition, the plasma level of S100P reduced significantly in response to the 96 
radiographic treatment of these patients [31].  97 
S100P is also involved in drug response in different cancer types, either by increasing 98 
chemoresistance [9; 32] or enhancing chemosensitivity [33; 34]. S100P overexpression is 99 
related to the resistance to 5-fluorouracil in pancreatic cancer [9] and irinotecan in prostate 100 
cancer [35]. There is a correlation between overexpression of S100P and resistance to 101 
cyclophosphamide, etoposide, methotrexate and mitoxantrone in different cancer cell lines [32]. 102 
S100P also binds  p53, together with its negative regulator HDM2, and perturbs the p53-103 
HDM2 complex binding and increases the p53 level. However, the S100P-induced p53 is not 104 
able to activate its transcriptional targets (e.g. hdm2, p21WAF, and bax) following the DNA 105 
damage and enhances chemoresistance by binding and inactivating p53 [36]. In contrast to the 106 
above findings, studies on ovarian cancer cells show a chemo-sensitization effect of S100P in 107 
response to drugs including carboplatin and paclitaxel, 5-fluorouracil, etoposide and 108 
doxorubicin [33]. Similarly, studies on the downregulation of S100P in colon cancer cell line 109 
8307 suggest that S100P is associated with oxaliplatin sensitivity in the drug-resistant cells 110 
[34]. These findings suggest that either drug resistance or sensitivity may be regulated by 111 
S100P in different cancers.  112 
Until now the role of S100P in the response of breast cancer to chemotherapeutic drugs remains 113 
unclear. In this study, we collected breast tissue samples from 22 pairs (pre-chemo and post-114 
chemo) of breast cancer tissues from patients who underwent neoadjuvant chemotherapy. 115 
Immunohistochemistry was used to investigate expression levels of S100P protein, and 116 
changes between pre-chemotherapy and post-chemotherapy were analysed. Using T47D and 117 
SK-BR-3 breast cancer cell lines, the influence of S100P on cell behaviour, biological function, 118 
and chemosensitivity was explored in vitro. 119 
2. Materials and methods 120 
2.1. Cell lines and culture 121 
The human breast cancer cell lines including T47D and SK-BR-3 were obtained from ATCC 122 
(Middlesex, UK). The cells were subcultured at 37°C, 5% CO2 in Dulbecco’s Modified Eagle’s 123 
Medium (DMEM/Ham’s F-12 with L-Glutamine) (Sigma-Aldrich, Dorset, UK) supplemented 124 
with 1X antibiotics penicillin and streptomycin (Sigma-Aldrich, Dorset, UK) and 10% fetal 125 
bovine serum (FBS) (Sigma-Aldrich, Dorset, UK).  126 
2.2. Stable cell lines with S100P knockdown 127 
To establish the stable S100P knockdown breast cancer cell lines, lentiviral-derived vectors 128 
containing S100P shRNA(pLV[shRNA]-EGFP:T2A:Puro-U6>hS100P[shRNA#1]) or 129 
Scramble shRNA (Scr) negative control (pLV[shRNA]-EGFP:T2A:Puro-130 
U6>Scramble_shRNA) were transfected into T47D and SK-BR-3 cells (Vector builder, USA) 131 
based on the manufacturer's protocol. Briefly, 5×104 cells were loaded into a 6-well plate, 132 
incubated overnight, and changed to medium with 10 µg/ml of polybrene and lentiviral 133 
particles. After incubation for 20 hours, normal medium was used for subsequent culture for 3 134 
days. Puromycin (Sigma, St. Louis, MO, USA), at a concentration of 2 µg/ml, was applied for 135 
the specific selection of the stable cells. After selection for one week, the stable cells were 136 
cultured in normal medium with the addition of 0.25 µg/ml puromycin for the maintenance of 137 
the stable cell property. 138 
2.3.Quantitative real-time PCR（q-PCR） 139 
Total RNA was extracted from cultured cells using TRIzol reagent (Sigma-Aldrich, Dorset, 140 
UK) following the manufacturer's instructions. RNA was reverse transcribed into cDNA using 141 
the GoScript™ Reverse Transcription System kit (Promega, Madison, WI, USA). The 142 
quantitative real-time PCR was performed with an iCycler iQ™ (Bio-Rad Laboratories, Hemel 143 
Hempstead, UK) following the cycling conditions: 94°C for 5 min, 100 cycles of 94°C for 10 144 
sec, 55°C for 35 sec and 72°C for 20 sec. The primer sequences of S100P were: F: 145 
ATCATAGACGTCTTTTCCCG; zR: ACTGAACCTGACCGTACA 146 
CACTTGAGCAATTTATCCACGG (Z sequence is highlighted in bold font). The mRNA 147 
levels were normalised to those of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 148 
using the method of 2-ΔCt. 149 
2.4.Western blotting 150 
Cultured cells were detached and lysed with a protein lysis buffer. Protein concentration was 151 
measured using a Bio-Rad DC protein assay kit (Hemel-Hempstead, UK). Equal amounts of 152 
protein samples were separated by sodium dodecyl sulphate-polyacrylamide gel 153 
electrophoresis (SDS-PAGE) and blotted to PVDF membrane. The membrane was then 154 
blocked with 5% skimmed milk for 2 hours. Proteins were specifically probed with a primary 155 
antibody and peroxidase-conjugated secondary antibody respectively. Protein signals were 156 
visualised with a Luminata Forte Western HRP substrate (Merck Millipore, Hertfordshire, UK) 157 
and assessed by Image J software (National Institutes of Health, Bethesda, MD, USA) based 158 
on the intensity of the blotted bands.  159 
The antibodies of S100P (#ab133554), NF-κB (p65) (#ab16502) and Vimentin (#ab137321) 160 
were acquired from Abcam (Cambridge, UK). GAPDH (#sc-47724), CCND1 (#sc-8396) 161 
antibodies were obtained from Santa Cruz (Insight Biotechnology Limited, Middlesex UK). E-162 
cadherin (#AF748) was purchased from R & D Systems (Abingdon, Oxfordshire, UK). Anti-163 
mouse (#A5278), anti-rabbit (#A0545) secondary antibodies were purchased from Sigma-164 
Aldrich (Gillingham, Dorset, UK). 165 
2.5.Cell proliferation and cytotoxicity assays 166 
AlamarBlue assay was used to assess cell proliferation ability. Briefly, 3×103 cells (T47D) or  167 
5×103 cells (SK-BR-3) per well were seeded into a 96-well cell culture plate and incubated for 168 
6 days. At the designated time points (Day 0, 2, 4 and 6), the culture medium was aspirated out 169 
and 100 µl of normal medium with 10 µl of the AlamarBlue reagent (Serotec Ltd., Oxford, UK) 170 
was added to each well. Cells were then incubated for 3 hours at 37˚C. The fluorescence signal 171 
was determined with a fluorescence plate reader (Promega, Southampton, UK) with excitation 172 
at 525nm and emission at 590nm. The percentage of proliferation during the incubation period 173 
was normalized with the fluorescence values at Day 0. 174 
For the cytotoxicity assay, 1×104 cells per well were loaded into a 96-well plate with a starving 175 
medium containing 1% FBS. After incubation overnight, the medium was changed with normal 176 
medium containing serial concentrations of paclitaxel (Sigma-Aldrich, UK) or cisplatin 177 
(Sigma-Aldrich, UK), respectively, and cultured for 48 hours; cell cytotoxicity was then 178 
evaluated by the AlamarBlue assay described above. 179 
2.6.Scratch wound assay 180 
Cells were loaded into a 24-well plate at a density of 2×105 cells/well and cultured to reach 181 
confluence. The cell monolayer was then scratched with a 1 ml pipette tip to generate an 182 
artificial wound. After being washed twice with phosphate-buffered saline (PBS), 1 ml normal 183 
medium was added to each well. The migration of cells across the wound gap was monitored 184 
using an EVOS® FL imaging system (Life Technologies, Carlsbad, CA, USA) with a 4X 185 
objective every 2 hours for 48 hours. The percentage of the gap closed area was measured and 186 
normalised by the data at Hour 0 using the Image J software. 187 
2.7.Matrigel invasion assay 188 
A transwell Matrigel assay was applied to evaluate the invasive ability of cells in vitro. Briefly, 189 
transwell inserts (8 µm pores) for a 24-well plate were pre-coated with 0.5 mg/ml Matrigel (BD 190 
Bioscience, Oxford, UK) for 1 hour at 37˚C. Subsequently, 2×105 cells were loaded into the 191 
upper chamber in 150 µl of DMEM. The lower chamber was filled with 650 µl of normal 192 
medium. After incubation for 48 hours, cells on the top side of the inserts were removed using 193 
a cotton swab. Chambers were fixed with 4% formalin for 30 minutes, and stained with 1% 194 
crystal violet for 30 minutes before rinsing with PBS. The number of invasive cells (underneath 195 
the inserts) was calculated by counting under a microscope (at least five counts per 196 
experimental setting).  197 
2.8.Cell-matrix adhesion assay 198 
A 96-well plate was pre-coated with Matrigel (10 µg/well) for 2 hours at 37°C. 5×104 cells 199 
were then added to each well and cultured for 4 hours, followed by washing twice with PBS. 200 
Adhesive cells were fixed with 4% formalin and stained with 1% crystal violet. The number of 201 
adhesive cells was counted under a microscope (at least five counts per experimental setting).  202 
2.9.Patients and specimens 203 
The study protocol was approved by the Ethics Committee of Yantai Yuhuangding Hospital 204 
(Approval NO. 2018-109). Consecutive breast cancer patients (n=22) who underwent 205 
neoadjuvant chemotherapy and surgery, from January 2017 to June 2017, were selected. All 206 
patients received ACx4 (Epirubicin and Cyclophosphamide) followed by Tx4 (Paclitaxel or 207 
Docetaxel) regimen for neoadjuvant chemotherapy. All patients recruited for this study were 208 
not pathological complete response after neoadjuvant chemotherapy in order to evaluate the 209 
differential expression level of S100P on tumor cells. During the same period, 10 cases of 210 
fibroadenoma were randomly selected as a control. Hormonal receptor status was determined 211 
by immunohistochemistry (IHC) described below. The HER2 status was examined following 212 
the American Society of Clinical Oncology guidelines. Based on the different combinations of 213 
ER, PR, HER2 and Ki67, patients were divided into four subgroups: luminal A, luminal B 214 
(luminal B HER2+ and luminal B HER2-), HER2+ and triple-negative. 215 
2.10. IHC 216 
Formalin-fixed and paraffin-embedded tissue sections were freshly cut (4 µm) and mounted on 217 
silane-coated slides. After deparaffination, the activity of endogenous peroxidase was blocked 218 
by exposure to 3% H2O2 for 5 minutes. All the sections were then boiled for 15 minutes at 219 
250W in the Antigen Retrieval Solution (Dako Cytomation, Denmark). Nonspecific binding 220 
was blocked with normal goat serum at room temperature for 20 minutes. Immunostaining was 221 
then carried out using the primary antibody S100P (1:100, Rabbit, #ab133554, Abcam) and 222 
incubated at 4°C overnight. After incubation for 25 minutes at room temperature using a 223 
biotinylated secondary antibody, slides were incubated with streptavidin–peroxidase complex 224 
(Avidin/Biotin Blocking Kit, #SP-2001, Vector Laboratories, Burlingame, CA, USA) for 25 225 
minutes. Staining was visualized with 3,3’-Diaminobenzidine (DAB) and Mayer's hematoxylin 226 
(1:10, Merck, Darmstadt, Deutschland) counterstain.  227 
The intensity of S100P expression was evaluated by two qualified pathologists independently 228 
using a semi-quantitative scale of the Immuno Reactive Score (IRS). Briefly, the staining 229 
intensity was scored as 0 = none, 1= weak, 2 = moderate, and 3 = high intensity. Additionally 230 
the percentage of positive stained cells was scored as 0 = no positive cells detectable, 1 = <10% 231 
of cells, 2 = 10-50% of cells, 3 = 51-80% of cells and 4 = >80% of cells. For the IRS, both 232 
scores were multiplied. The cases were divided into two groups showing no or weak staining 233 
(S100P: IRS< 4) and strong staining (S100P: IRS ≥ 4) [23].  234 
2.11. Statistical analysis 235 
Statistical analyses were performed using SPSS v25.0 (IBM Corporation, New York, United 236 
States). Two-group comparisons were analysed by a two-sided t-test when data were normally 237 
distributed, or Mann-Whitney U test when data were not normally distributed. Nonparametric 238 
test of two paired samples (Wilcoxon signed-rank test) or independent sample (Mann-Whitney 239 
or Kruskal-Wallis H(K)) was used to analyse the IHC results. Differences were defined as 240 
statistically significant when p-values were less than 0.05. In vitro experiments were repeated 241 
2-4 times unless otherwise stated. The significance was shown in the figures as follows: 242 
*p<0.05; **p<0.01; ***p<0.001, and the p>0.05 (no significance) was not shown. 243 
3. Results 244 
3.1.S100P is upregulated in breast cancer and associated with poor prognosis 245 
The expression levels of S100P in 22 cases of breast cancer tissue samples before and after 246 
neoadjuvant chemotherapy, and 10 cases of breast fibroadenoma were detected by IHC. The 247 
results indicated that expression levels of S100P in breast cancer were higher than those in 248 
fibroadenoma (p<0.001) (Figure 1A). 6 out of 22 (27.27%) breast cancer patients showed 249 
strong staining of S100P, especially in Luminal B HER2+ subtype (4/4) (p=0.041) (Figure 1B). 250 
In contrast, 9 out of 10 fibroadenoma patient samples did not show the expression of the S100P 251 
protein, with only one sample showing weak staining of S100P (Figure 1C). S100P protein was 252 
mainly located in the nucleus of the cells, with some cytoplasmic and cytomembrane staining 253 
(Figure 1D). 254 
To verify our findings, we analyzed the TCGA breast cancer database and found that S100P 255 
gene expression levels in breast cancer tissue were higher than those in normal tissue (p<0.001) 256 
(Figure 1E), which was consistent with our results. The expression levels of S100P in HER2+ 257 
breast cancer were higher than those in other subtypes (Figure 1F). S100P levels in patients 258 
with N3 lymph node metastasis was dramatically higher than that in N2 and normal tissues, 259 
and N2>N1, N1>N0 similarly (all p<0.05, Figure 1G), which suggested that S100P may be 260 
involved in breast cancer metastasis. 261 
We further used the KM plotter breast cancer database to explore the prognostic significance 262 
of S100P in breast cancer. As shown in Figure 1H, the high expression of S100P was closely 263 
associated with the poor recurrence-free survival (RFS) (p<0.001) (Figure 1H) and overall 264 
survival (OS) (p<0.001) (Sup Figure 1). For all different subtypes of breast cancer, high 265 
expression levels of S100P were all related to poor prognosis (Data was not shown). 266 
3.2.S100P increases cell proliferation and adhesion in vitro 267 
To investigate the function and mechanism of S100P in breast cancer, stable cell lines knocking 268 
down S100P by lentivirus siRNA transfection were established in T47D and SK-BR-3 cells. 269 
Assessed by qRT-PCR and western blot, levels of S100P were significantly decreased at both 270 
gene level (decreased at least 200%) and protein level (not detected) after S100P was knocked 271 
down (Figure 2A). This confirmed that stable cell lines with a low level of S100P were 272 
successfully constructed. 273 
Cell proliferation assay was carried out in vitro, with results showing that the proliferative 274 
ability of T47D cells with a low level of S100P was significantly decreased by 15.04% (Day 2, 275 
p<0.01. Figure  2B). Similarly, the proliferative ability of SK-BR-3 cells with low levels of 276 
S100P was decreased by 12.18% on Day 4 and 9.34% on Day 6 (p<0.01. Figure  2C). These 277 
findings indicated that S100P promoted cell proliferation.  278 
The effect of S100P on the adhesion of breast cancer cells was assessed by Matrigel adhesion 279 
assay in vitro. As shown in Figure 2D-2I, the adhesive ability of breast cancer cells decreased 280 
in both T47D by 84.32% and SK-BR-3 cells by 56.51% after the knockdown of S100P 281 
(p<0.001, respectively). 282 
3.3.S100P increases cell invasion and migration in vitro 283 
To explore the influence of S100P on the invasion and migration of breast cancer cells, we 284 
conducted a transwell Matrigel assay and cell scratch experiment. As shown in Figure 3E-3H, 285 
the invasive ability of breast cancer cells with low levels of S100P decreased significantly 286 
(T47D by 76.27%, p<0.001; SK-BR-3 by 35.97%, p<0.01) (Figure 3A-3D). Similarly, the 287 
migration of breast cancer cells with low levels of S100P decreased significantly both in T47D 288 
and SK-BR-3 cells (T47D by 19.72%, 48h, p<0.05; SK-BR-3 by 19.16%, 48h, p<0.01).  289 
3.4.S100P enhances the chemosensitivity of breast cancer cells 290 
To explore the role of S100P in chemotherapeutic drug sensitivity in breast cancer, T47D (with 291 
Luminal HER2- subtype) and SK-BR-3 (with HER2+ subtype) cells were treated with different 292 
concentrations of paclitaxel and cisplatin, and cell viability was assessed by AlamarBlue assay. 293 
Results showed that expression levels of S100P did not affect paclitaxel sensitivity between 294 
T47D Scr and S100P KD cells (Figure 4A). However, at concentrations of 5 nM (p<0.01), 10 295 
nm (p<0.001), 20 nM (p<0.001) and 40 nM (p<0.001), the SK-BR-3 S100P KD cells were 296 
significantly more resistant to the cytotoxic effects of paclitaxel than the Scr cells by 21.02%, 297 
46.62%,118.69% and 129.36%, respectively (Figure 4B). These results suggest that tumours 298 
with high expression levels of S100P are more sensitive to paclitaxel chemotherapy in HER2+ 299 
breast cancer cells (SK-BR-3). 300 
Furthermore, we evaluated the effect of S100P on the chemosensitivity of breast cancer cells 301 
to cisplatin. As shown in Figure  4C, T47D S100P KD cells were more sensitive to low 302 
concentrations of cisplatin compared with T47D Scr cells by 18.09% (8 µm, p<0.01), but there 303 
was no significant difference at high concentrations of cisplatin. For SK-BR-3 cells, the SK-304 
BR-3 S100P KD cells were more resistant to cisplatin compared with Scr cells  (4 µM by 305 
30.51%, 16 µM by 89.67%, 32 µm by 139.49%, 64 µM by 898.97%, all p<0.001; 8 µM by 306 
28.77%, p<0.05), indicating that the tumour with high S100P expression is more sensitive to 307 
cisplatin chemotherapy (Figure  4D). 308 
3.5.The knockdown of S100P alters the expression of CCND1 and EMT-associated molecules.  309 
We conducted Western blotting to unveil the mechanisms that S100P modulated the behaviours 310 
of breast cancer cells. As shown in Figure 4E and 4F, expression levels of the cyclin-D1 311 
(CCND1) protein in T47D S100P KD cells and SK-BR-3 S100P KD cells were all decreased 312 
by 11.97% and 22.62% compared to their Scr controls. This suggests that S100P promoted cell 313 
proliferation by activating CCND1 protein in breast cancer. 314 
We also detected the alteration of EMT related proteins after S100P was knocked down. 315 
Expression levels of E-cadherin in T47D S100P KD cells increased by 33.53% (Figure 4E and 316 
4F), while expression levels of vimentin decreased both in T47D S100P KD cells by 21.59% 317 
and SK-BR-3 S100P KD cells by 32.00%. These findings indicated that S100P increased cell 318 
migration and invasion by regulating E-cadherin and vimentin. 319 
3.6.Levels of S100P protein is reduced in tumour tissue after chemotherapy  320 
To verify the role of S100P in chemosensitivity of breast cancer cells, expression levels of 321 
S100P in 22 pairs of breast cancer tissue samples before and after neoadjuvant chemotherapy 322 
were examined by immunohistochemistry. This revealed that the expression levels of S100P 323 
in tumour tissue decreased by 46.55% after chemotherapy, compared with before 324 
chemotherapy (p=0.015, Figure 5A). For subgroup analysis, S100P in HER2+ tumour tissue 325 
decreased by 57.58% after chemotherapy (p=0.027, Figure 5B), while there was no statistical 326 
difference in the change of S100P in the HER2- subgroup (p=0.942, Figure 5C), which 327 
suggested that HER2+ breast cancer cells with higher levels of S100P were more sensitive to 328 
chemotherapy. 329 
4. Discussion 330 
Metastasis and drug resistance are still tremendous challenges in breast cancer therapy leading 331 
to increased mortality. Therefore, identifying biomarkers of metastasis and elucidating 332 
mechanisms of drug resistance are of prime importance in breast cancer research.  333 
Our results provide evidence that expression levels of S100P in breast cancer are significantly 334 
higher than those in fibroadenoma. The presence of S100P in the early stages of breast 335 
carcinogenesis suggests that S100P may serve as a biomarker to differentiate lesions at high 336 
risk of malignant evolution [19]. Other studies have since reported that activation of HER2 337 
increases the expression of S100P in breast cancer cells [16]. The relation between S100P and 338 
HER2 overexpression is only significant for ER+ tumors [37], supporting that S100P may be 339 
associated with a hormone receptor-positive, HER2-enriched molecular subtype. In the present 340 
study, the expression levels of S100P is extremely high in Luminal B HER2+ breast cancer, 341 
which is supported by previous studies [37]. This phenomenon may be more related to the 342 
‘HER-enriched’ breast cancer subtype [38; 39], suggesting that S100P may have a potential for 343 
the categorisation of breast cancer and to be as a therapeutic target.  344 
S100P is localised intracellularly in the nucleus, cytoplasm and cell membrane. C-terminally 345 
truncated form of S100P (t-S100P) is the major form of S100P and is exclusively located in 346 
the nucleus of breast cancer cells. High t-S100P is strongly prognostic for poor DFS, its 347 
efficacy confined to lymph node-positive tumors [40]. Similar studies show patients with 348 
strong S100P nuclear expression have a significantly shorter OS and DFS [41; 42]. S100P is 349 
prominent among genes upregulated in primary breast cancer cells with high-grade tumors [43]. 350 
Likewise, its expression correlates to the level of the proliferative Ki-67 marker in primary 351 
breast cancer [17]. The survival of breast cancer patients with S100P-positive cancers is 352 
significantly worse than those negative for S100P [18; 44]. For TNBC patients, overexpression 353 
of S100P significantly correlates with more lymph node involvement, higher occurrence of 354 
metastasis and more recurrence events [23]. Through analyzing the KM plotter breast cancer 355 
database, our data further confirms that high expression of S100P is closely associated with 356 
poor RFS and OS in breast cancer patients, which indicates that S100P exhibits a strong link 357 
with tumor progression and prognosis in breast cancer. On the other hand, the extracellular 358 
S100 proteins affect several intracellular signaling pathways through interacting with cytokines. 359 
The interaction of S100P and IFN-β exhibits suppressed cytotoxicity towards MCF-7 breast 360 
cancer cells, implying that the antitumor activity of IFN-β is suppressed by S100P. This 361 
mechanism could explain the S100P action as a factor which promotes tumor growth, 362 
angiogenesis, metastasis, drug resistance and poor clinical outcome [45].  363 
Previous studies indicate that S100P regulates some important proteins including CCND1 [46] 364 
and E-Cadherin [47]. Our study demonstrates that S100P enhances cell proliferation by 365 
activating CCND1, and promotes cell migration and invasion through downregulating E-366 
cadherin and upregulating Vimentin in breast cancer in vitro. S100P is shown to promote 367 
cellular proliferation through binding with RAGE and activation of downstream molecules 368 
including ERKs, NF-κB and β-catenin [48]. S100P and Ezrin induce proliferation and 369 
migration in TNBC cells, and siRNA knockdown of Ezrin and S100P reduces the migration of 370 
these cells accompanied by an increased E-Cadherin expression [24]. Mechanistically, S100P 371 
induces EMT through binding to Integrin α7 and activation of the FAK (Focal Adhesion 372 
Kinase)/Src/Akt pathway, and upregulation of the expression of ZEB1 [47]. S100P, Ezrin and 373 
phospho-EzrinThr-567 are all involved in the transendothelial migration of TNBC cells and may 374 
act as potential targets in TNBC patients [24]. Moreover, transfection of a vector expressing 375 
S100P into a benign, non-metastatic rat mammary cells induces a three-fold increase in local 376 
muscle invasion and significant induction of metastasis in up to 75% of tumor-bearing animals, 377 
supporting the function of S100P as an inducer of breast cancer metastasis [44]. 378 
S100P not only promotes tumour progression and metastasis, but also plays a role in drug 379 
responses to chemotherapy, endocrine therapy and targeted therapy. S100P levels may have a 380 
predictive value of response to chemotherapy, although findings are controversial between 381 
different cancer types. The implication of S100P in breast cancer chemotherapeutic drug 382 
response may be complicated. From our present study, the expression levels of S100P in 383 
tumour tissue decrease dramatically after chemotherapy compared with pre-chemotherapy, 384 
indicating S100P may have a chemo-sensitive role in breast cancer. In vitro experiments show 385 
the expression of S100P does not affect paclitaxel sensitivity in T47D cells (Luminal B HER2- 386 
subtype), while T47D S100P KD cells are more sensitive to low concentrations of cisplatin 387 
(e.g. 8 µM). In agreement with these results in vitro, there is no statistical difference in the 388 
change of S100P in HER2 negative breast cancer patients through analyzing the changes of 389 
S100P protein between pre-chemo and post-chemo breast tissues. This demonstrates that 390 
S100P does not play a significant role in chemotherapeutic drug response in HER2- breast 391 
cancer. However, in the HER2+ breast cancer cell line SK-BR-3, SK-BR-3 S100P KD cells is 392 
significantly resistant to paclitaxel and cisplatin compared with the vehicle control. This is 393 
confirmed in neoadjuvant chemotherapy patients that the expression level of S100P in HER2+ 394 
tumour tissues decreases significantly after chemotherapy compared with pre-chemotherapy. 395 
Therefore, our findings imply that S100P may have a role in predicting the drug sensitivity in 396 
HER2+ breast cancers. The different responses to chemotherapy might due to the different 397 
subtypes of breast cancer. However, the mechanism of this phenomenon remains unclear and 398 
requires further investigation to elucidate.  399 
Resistance to hormone therapy is also a challenge for hormone receptor-positive breast cancers. 400 
ER+ breast cancer can escape antiestrogen treatment by up-regulating S100P [49]. In a MCF-401 
7 cell line with resistance to tamoxifen (TAM), the expression level of S100P is elevated. As 402 
the ER-regulated proliferation pathway is significantly suppressed after prolonged exposure to 403 
TAM, the S100P-RAGE signaling pathway via activation of ERK1/2 and NF-κB may be 404 
considered as a compensatory mechanism of cell proliferation and survival [41]. Histone 405 
deacetylase 9 (HDAC9)-overexpressing cells are less sensitive to hydroxytamoxifen (OHTAM) 406 
antiproliferative effects compared with parental MCF-7 cells through upregulating S100P [50]. 407 
Therefore S100P may serve as a significant player in conferring acquired TAM resistance [41]. 408 
Additionally, S100P is also involved in resistance to targeted therapies through activating the 409 
RAS/MEK/MAPK pathway to compensate for HER2 inhibition by trastuzumab, and inhibition 410 
of S100P leads to reversing the trastuzumab resistance [51]. It remains unknown whether 411 
S100P is also involved in resistance to hormone therapies and targeted therapies in HR+ 412 
HER2+ breast cancers, which may be the direction of further investigation. 413 
In conclusion, S100P enhances the proliferation, adhesion, migration and invasion of breast 414 
cancer cells through the regulation of NF-κB, CCND1, E-cadherin and vimentin. S100P could 415 
be a promising therapeutic target in certain types of breast cancer. Additionally, S100P may be 416 
a biomarker to predict the therapeutic effects of chemotherapeutic agents in treating HER2+ 417 
breast cancer patients. 418 
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 606 
Figure 1. Expression levels of S100P in breast cancer and its association with survival. (A) 607 
IHC showed that expression levels of S100P in breast cancer were significantly higher than 608 
breast fibroadenoma (p<0.001). (B) Expression levels of S100P in Luminal B HER2- subtype 609 
breast cancer were higher than other subtypes (p=0.041). (C) No S100P expression was 610 
observed in fibroadenoma tissue samples (IHCx200). (D) Strong S100P expression observed 611 
in breast cancer tissue samples (IHCx200). (E) S100P gene levels were significantly higher in 612 
breast cancer samples than in normal breast tissue, through the analysis of the TCGA breast 613 
cancer database (p<0.001).  (F) TCGA data showed that gene expression levels of S100P in 614 
HER2+ subtypes were higher than in other types. (G) TCGA data showed the gene expression 615 
levels of S100P in patients with lymph node metastasis (N3>N2, N2>N1, N1>N0) (all p<0.05). 616 
(H) KM-plotter database showed that the high expression level of S100P was associated with 617 
poor recurrence-free survival (RFS) in breast cancer patients (p<0.001). 618 
 619 
Figure 2. The effect of S100P on cell proliferation and adhesion in breast cancer. (A) S100P 620 
was knocked down in T47D and SK-BR-3 cells and validated by qRT-PCR and western blot. 621 
(B) S100P knocking down decreased cell proliferation in T47D cells (2 days, p<0.01) (n=10 622 
per group). (C). S100P knocking down decreased cell proliferation in SK-BR-3 cells (4 and 6 623 
days, p<0.01) (n=10 per group). (D-F). S100P knocking down reduced adhesive ability in 624 
T47D cells (p<0.001). (G-I) S100P knocking down reduced adhesive ability in SK-BR-3 cells 625 
(p<0.001).  626 
 627 
Figure 3. The effect of S100P on invasion and migration of breast cancer cells in vitro. (A-B) 628 
Invasive ability was significantly decreased in T47D cells after S100P was knocked down 629 
(p<0.001). (C-D) Invasive ability was significantly decreased in SK-BR-3 cells after S100P 630 
was knocked down (p<0.01). (E-F) Migrative ability was decreased in T47D cells after 631 
S100P was knocked down (48h, p < 0.05) (n=7 per group). (G-H) Migrative ability was 632 
decreased in SK-BR-3 cells after S100P was knocked down (48h, p<0.01) (n=14 per group). 633 
 634 
Figure 4. The effect of S100P on chemotherapeutic drug response in T47D and SK-BR-3 cells. 635 
(A). S100P did not affect the paclitaxel sensitivity in T47D cells  (n=6 per group). (B). SK-636 
BR-3 S100P KD cells were significantly more resistant to paclitaxel (n=6 per group). (C). 637 
T47D S100P KD cells were more sensitive to low concentration cisplatin compared with the 638 
Scr control (8 µm, p<0.01) (n=6 per group). (D) SK-BR-3 S100P KD cells were more resistant 639 
to cisplatin compared with the Scr cells (n=6 per group). (E) Protein levels of NF-κB, CCND1, 640 
E-cadherin and Vimentin assessed by western blot after S100P was knocked down in T47D 641 
and SK-BR-3 cells, respectively.  (F) Quantitative densitometric analysis of western blots using 642 
Image J software. 643 
 644 
Figure 5. Expression levels of S100P in breast cancer tissue samples before and after 645 
neoadjuvant chemotherapy, detected by immunohistochemistry. (A) S100P levels in tumour 646 
tissue decreased significantly after chemotherapy (p=0.015). (B) S100P levels in HER2+ 647 
tumour tissue decreased significantly after chemotherapy (p=0.027). (C) The change of 648 
S100P levels in HER2 negative patients between pre-chemo and post-chemo was not 649 
significant (p=0.942). (D-M) IHC of S100P expression pre-chemotherapy and post-650 
chemotherapy in different subtypes of breast cancer patients (x200). 651 
 652 
Supplement Table 1. The scores of IHC of S100P in breast cancer tissue samples before and 653 
after neoadjuvant chemotherapy.  654 
 655 
Supplement Figure 1. Overall survival (OS) analysis of the S100P gene in breast cancer by 656 
KM plotting.   657 
 658 
Supplement Figure 2. Representative images of the positive and blank controls of the IHC.  659 
